TScan Therapeutics, Inc.
About TScan Therapeutics, Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $10.3M
- Net income
- -$129.8M
- Total assets
- $228.8M
- Market cap
- $64.2M
- Operating margin
- -1315.4%
- Net margin
- -1256.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $10.3M
- Operating expenses
- $146.1M
- Operating income
- -$135.8M
- Income tax
- $0
- Net income
- -$129.8M
- EPS (basic)
- $-1.00
- EPS (diluted)
- $-1.00
Balance sheet
- Total assets
- $228.8M
- Current assets
- $157.2M
- Total liabilities
- $105.7M
- Current liabilities
- $18.7M
- Shareholders’ equity
- $123.1M
Cash flow
- Operating cash flow
- -$135.3M
- Investing cash flow
- $109.4M
- Financing cash flow
- -$336.0K
- Net cash flow
- -$26.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $64.2M
- EPS (diluted)
- $-1.0
- Shares outstanding
- 64.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 16, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $129.8M in FY2025.
- Revenue grew 2% from FY2021 to FY2025.
- Trading 61% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TScan Therapeutics, Inc..
Write a review
News about TScan Therapeutics, Inc.
News & sentiment via Polygon.io
